Developing Robust In Vitro Cell-Based Assays for High Throughput Screening (HTS)

Introduction

Cell-based high throughput screening (HTS) platforms have significantly accelerated drug discovery by providing high-content, scalable, and clinically relevant data early in the screening pipeline.  Cell-based assays have become indispensable tools in HTS, enabling researchers to rapidly evaluate thousands to millions of molecules for biological activity. For how an assay is taken from development through GMP validation, see our guide to cell-based assay development. In the context of high throughput screening of molecules in cell-based assays, the term ‘library’ refers to a large, systematically organized collection of chemical or biological compounds that are catalogued for the purpose of being rapidly and efficiently tested.  A wide range of distinct libraries, based on molecular design and mechanism, have been screened using HTS, and include for example, small molecules, RNAi, peptide and CRISPR-Cas9 libraries.  The stepwise HTS library screening typically involves seeding cells in multi-well plates, treating them with molecules of interest, and employing sensitive detection methods—such as fluorescence or luminescence—to assess cell viability and other functional endpoints.

For drug discovery in vitro cell-based assays measure responses such as viability, proliferation, toxicity, and changes in signaling pathways, offering a closer approximation to human biology than traditional biochemical assays.  Developing robust cell viability assays for HTS requires careful testing of assay conditions, such as selection of appropriate cell models (including immortalized, primary, or stem cells), assay sensitivity and reproducibility.  These assay requirements ensure reliable identification of molecules that are active.

Multiple detection methods for determining a specific cellular response in HTS, including those listed below, are taken to evaluate molecular libraries for activity in cell-based assays.

In vitro cellular response assays used for high-throughput drug screening.

  • Cell Viability / Proliferation Assays
    Measure cell growth, or death in response to compounds, often using colorimetric (MTT, XTT), luminescent (ATP-based), or fluorescent readouts.
  • Reporter Gene Assays
    Use cells engineered to express a detectable reporter (e.g., luciferase, GFP) under control of a specific promoter, indicating pathway activation or inhibition.
  • High-Content Screening (HCS) / High-Throughput Microscopy
    HCS combines high-resolution microscopy, fluorescent labeling, and sophisticated image analysis. Allows automated imaging and analysis of cellular phenotypes (morphology, organelle structure, protein localization).
  • Cell Painting Assays
    Multiplexed fluorescent staining of cellular components, followed by high-content imaging and computational analysis to predict bioactivity and mechanism of action.
  • Calcium Flux Assays
    Use fluorescent indicators to monitor changes in intracellular calcium, often used for screening compounds affecting ion channels or GPCRs.
  • Second Messenger Assays (e.g., cAMP, IP3)
    Detect changes in intracellular signaling molecules, commonly using biosensors or reporter systems.
  • Cell-Based Toxicity Assays
    Assess cytotoxic effects of compounds, including apoptosis, necrosis, or specific organelle damage (e.g., mitochondrial toxicity).

Advances in automation, imaging, and data analysis have greatly expanded the scope and power of cell-based high-throughput screening in drug discovery.

The stepwise process of HTS for drug screening is similar for distinct cellular responses. Evaluating viability of cells using HTS is one example of an endpoint read-out and highlights the need for a robust reproducible assay.

Stepwise Process for Drug High-Throughput Screening (HTS) Using In Vitro Cell-Based Viability Assays

1. Plating Cells in Multi-Well Tissue Culture Plates

  • Selection of Plates: Use standardized multi-well plates (e.g., 96-, 384-, or 1536-well plates) that are tissue culture-treated for optimal cell adhesion and growth. These plates are designed for compatibility with automated liquid handling and plate readers.
  • Automated Cell Dispensing: Employ automated liquid handling systems or multichannel pipettors to dispense cells uniformly into each well. Automation ensures consistency and scalability, which is critical for HTS. Devices such as multichannel plating units or robotic dispensers can rapidly seed large numbers of plates, minimizing variability and manual error.
  • Incubation: After plating, incubate the plates under appropriate humidified conditions (e.g., 37°C, 5% CO₂) to allow cells to adhere and reach the desired confluency before drug addition.

 
2.  Adding Individual Drugs from a Large Library Source

  • Compound Library Preparation: Drugs are typically stored in master plates (often 96- or 384-well format) at known concentrations.
  • Automated Compound Transfer: Use robotic liquid handlers or acoustic dispensers to transfer precise volumes of each drug from the library plates to the assay plates. This process can be programmed for single or multiple concentrations (dose-response) and is highly scalable for thousands of compounds.
  • Controls: Include positive and negative controls on each plate to ensure assay validity and to normalize results.

 
3.  Cell Viability Assays Amenable to HTS

  • Assay Selection: Choose assays that are homogeneous (no wash steps), sensitive, and compatible with automation. Common HTS-compatible cell viability assays include:
  • ATP-based luminescent assays (e.g., CellTiter-Glo): Measure cellular ATP as a proxy for viable, metabolically active cells. These are highly sensitive and generate a luminescent signal proportional to cell viability.
  • Resazurin reduction assays (e.g., Alamar Blue): Fluorescent or colorimetric readout based on metabolic reduction of resazurin to resorufin by viable cells.
  • Tetrazolium salt assays (e.g., MTT, XTT, WST-1): Colorimetric assays based on reduction of tetrazolium salts to formazan by cellular enzymes.

 
4.  Plate Reader Detection for Cell Viability

  • Automated Plate Reading: After the viability reagent incubation, use a microplate reader (luminescence, fluorescence, or absorbance, depending on the assay) to detect and quantify the signal from each well6.
  • Integration with Robotics: Modern HTS setups integrate plate readers with robotic plate handlers, allowing for continuous, unattended reading of large batches of plates.
  • Data Analysis: The plate reader software collects and analyzes the signal intensity, which is proportional to cell viability. Results are normalized to controls and can be processed using specialized HTS analysis software for hit identification and quality control.

Approach for Developing a Cell Viability Assay for High Throughput Drug Screening

A robust and reproducible cell-based assay is essential for high-throughput screening because it ensures that experimental results are reliable, comparable, and meaningful across large-scale screens. Careful selection of assay type, cell line, and culture conditions, alongside rigorous optimization of variables such as seeding density, incubation time, and reagent concentrations, is critical to minimize variability and maximize the assay’s signal-to-noise ratio. Incorporating appropriate controls and normalization steps further strengthens data quality by accounting for plate-to-plate and experimental variability. The goal is to rapidly and reliably assess the effects of thousands of compounds on cell health, typically using multi-well plate formats.  Ultimately, a well-validated assay with high sensitivity, specificity, and dynamic range enables the consistent identification of active compounds, reduces false positives and negatives, and supports the discovery of true biological effects, making it a cornerstone of successful HTS campaigns. The Table below describes key variables that need to be addressed for developing a successful cell-based assay.

Key Steps and Variables

StepKey Considerations & ActionsExample Methods
Selection of Assay Type– Choose readout: – Each readout detects different viability aspects (metabolic activity, membrane integrity, ATP levels)..– Colorimetric: MTT/XTT
– Fluorescence: Calcein AM, Propidium Iodide
– Luminescence: ATP, Caspase-3
Cell Line & Culture Conditions– Select a cell line relevant to the biological question or disease.
– Optimize seeding density for linear response, avoiding overcrowding or under representation.		– Use disease-relevant cell lines
– Titrate cell number per well
Assay Optimization Variables– Determine optimal incubation time post-drug addition for viability measurement.
– Titrate reagent concentrations for best signal-to-noise and minimal toxicity.		– Vary incubation times (e.g., 24, 48, 72, 96 hrs)
– Adjust dye/substrate concentrations
Controls & Normalization– Use positive controls (known cytotoxic molecules) to define maximal response.
– Use negative controls (vehicle only) to set baseline.		– Positive: Staurosporine
– Negative: DMSO
– Normalize to control wells
Assay Performance Metrics– Assess sensitivity and specificity for distinguishing viable / non-viable cells and cytostatic / cytotoxic effects.
– Evaluate robustness and reproducibility (- Ensure broad dynamic range.		– Z’-factor calculation
– Signal window assessment 1
Data Analysis Considerations– Generate dose-response curves to determine IC50 / EC50
– Apply statistical tools to identify actives and control for variability.		– Dose-response analysis
– Statistical hit calling

Conclusion

In conclusion, cell-based assays are indispensable for high-throughput drug screening due to their ability to provide biologically relevant data on compound efficacy, mechanism of action, and potential toxicity within the context of living cells. These assays not only offer a more accurate representation of how drug candidates will behave in vivo but also enable the rapid and efficient evaluation of large compound libraries, accelerating the identification and optimization of promising therapeutic leads. However, the reliability and translational value of these findings depend heavily on the development of robust, reproducible, and physiologically relevant assays. Ensuring assay robustness minimizes false positives and negatives, enhances reproducibility, and ultimately increases the likelihood that hits from screening campaigns will translate into clinically effective drugs. As drug discovery continues to evolve, investing in the design and validation of robust cell-based assays remains a critical priority for advancing safe and effective therapies.

 

About Marin Biologic Laboratories, Inc.

Our Recent Publication/Meeting Presentation on Gene Therapy

1.  Development of a Pharmacokinetic (PK) Mouse Serum GLP ELISA for an Anti–CD19–AntiCD3 Diabody
bioRxiv 2025.03.19.644217; doi: https://doi.org/10.1101/2025.03.19.644217
2. Cell-Based Potency Assay for Anti-CD3-Anti-CD19 Diabody. bioRxiv 2025.04.15.648836v1 https://www.biorxiv.org/content/10.1101/2025.04.15.648836v1
3.  American Society of Hematology (ASH) Annual Meeting 2024.
Abstract link: Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity  Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager.

Comprehensive Assay Solutions for In Vitro and Cell Based Potency Assays and Pharmacokinetics Studies- Our Expertise

With 30 years of expertise in cell culture, cell-based assays, and preclinical/clinical PK/PD analysis, we specialize in offering assay services essential for a wide variety of therapeutic drug development programs, preclinical studies, IND/BLA applications, and commercialization. Our comprehensive services include both preclinical non-GLP and GLP assays, as well as non-GMP and GMP assays, providing critical support throughout the entire development pipeline.

Watch the following video and explore our latest presentation on the development and validation of potency and pharmacokinetic (PK) assays for AAV vectors, highlighting innovative methodologies and industry-leading expertise.

 

 

Download the full presentation: Development of Custom Cell Based and In vitro Potency and Pharmacokinetics (PK) Assays for AAV vectors- Marin biologic Laboratories

 

Development of Cell-Based Potency Assays: Case Studies and Blogs from Marin Biologic Laboratories (MarinBio)

Drug Discovery & Development Assays Offered by Marin Biologic Laboratories (MarinBio)